Active shortage

Enbrel 50 mg/mL injection

etanercept · 50 mg/mL injection

Enbrel

Reported
3 March 2025
Expected resolution
30 November 2025
TGA reference
TGA-MSI-2025-044
Sponsor
Pfizer Australia Pty Ltd

Reason for shortage

Pfizer biologic manufacturing capacity constraints. Rheumatoid arthritis and psoriasis patients must not stop biologic without specialist guidance.

What to do

  1. 1.
    Contact your pharmacistYour pharmacist can check current stock levels and advise on nearby pharmacies that may have supply. They can also assist with early dispensing to avoid running out.
  2. 2.
    Ask your doctor about alternativesYour GP or specialist can review whether a therapeutically equivalent alternative is appropriate for your situation. Never switch medicines without medical guidance.
  3. 3.
    Request early repeat if eligibleIf you have active repeats, your pharmacist may dispense an early repeat to build a short buffer supply while the shortage persists.
  4. 4.
    Check TGA for updatesThe TGA Medicine Shortage Information (MSI) database is updated regularly with expected resolution dates and approved substitutions.
  5. 5.
    Consider compounding if appropriateFor some medicines (particularly oral liquids or specific doses), a compounding pharmacist may be able to prepare an equivalent formulation.

Suggested alternatives

Same or related therapeutic class. Always discuss with your doctor or pharmacist before switching.

Official resources

MedWatch is for informational purposes only and does not constitute medical advice. Never stop or change your medicines without consulting your doctor or pharmacist. In an emergency, call 000. Medication queries: National Medicines Line 1300 633 424.